CL2022001888A1 - Nuevo derivado de pirazol - Google Patents

Nuevo derivado de pirazol

Info

Publication number
CL2022001888A1
CL2022001888A1 CL2022001888A CL2022001888A CL2022001888A1 CL 2022001888 A1 CL2022001888 A1 CL 2022001888A1 CL 2022001888 A CL2022001888 A CL 2022001888A CL 2022001888 A CL2022001888 A CL 2022001888A CL 2022001888 A1 CL2022001888 A1 CL 2022001888A1
Authority
CL
Chile
Prior art keywords
pyrazole derivative
new pyrazole
new
salt
pharmaceutical composition
Prior art date
Application number
CL2022001888A
Other languages
English (en)
Inventor
Jin Lee Soo
Hwan Moon Sung
Sil Lee Eun
Jung Shin Eun
Goh Yoo-Kyung
Chan Lee Sung
Kyung Yu Hyun
Ho Soo
Ban
Original Assignee
Aptabio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptabio Therapeutics Inc filed Critical Aptabio Therapeutics Inc
Publication of CL2022001888A1 publication Critical patent/CL2022001888A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un compuesto derivado de pirazol novedoso representado por la fórmula química I o una sal del mismo, y una composición farmacéutica que comprende el mismo.
CL2022001888A 2020-01-13 2022-07-12 Nuevo derivado de pirazol CL2022001888A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20200004471 2020-01-13

Publications (1)

Publication Number Publication Date
CL2022001888A1 true CL2022001888A1 (es) 2023-02-24

Family

ID=76864348

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001888A CL2022001888A1 (es) 2020-01-13 2022-07-12 Nuevo derivado de pirazol

Country Status (13)

Country Link
US (1) US20230067461A1 (es)
EP (1) EP4105206A1 (es)
JP (1) JP2023511302A (es)
KR (1) KR102333863B1 (es)
CN (1) CN114945561A (es)
AU (1) AU2021208915B2 (es)
BR (1) BR112022013849A2 (es)
CA (1) CA3167675A1 (es)
CL (1) CL2022001888A1 (es)
CO (1) CO2022010431A2 (es)
IL (1) IL294674A (es)
MX (1) MX2022008665A (es)
WO (1) WO2021145655A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023536764A (ja) * 2021-02-25 2023-08-29 アプタバイオ セラピューティクス インコーポレイテッド 新規なピラゾール誘導体
TW202334109A (zh) * 2022-02-25 2023-09-01 南韓商阿普塔生物治療公司 新穎吡唑衍生物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK574976A (da) * 1976-01-16 1977-07-17 Du Pont Substituerede cycloalkanpyrazoler samt deres fremstilling og anvendelse
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
KR100863692B1 (ko) * 2006-12-08 2008-10-15 울산대학교 산학협력단 퇴행성질환 및 염증질환에 대한 예방치료 효과를 갖는7-하이드록시-6-메톡시-1,2,3,4-테트라하이드로이소퀴놀린유도체
EP2151433A1 (en) * 2008-08-05 2010-02-10 Institut Pasteur Alkoxypyrazoles and the process for their preparation
TWI389913B (zh) * 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
FR2953839A1 (fr) * 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
EP2361911A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361912A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
KR20120098462A (ko) * 2011-02-28 2012-09-05 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
TWI599567B (zh) * 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
JP6527167B2 (ja) 2014-03-27 2019-06-05 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＳ１阻害剤としての置換４，５，６，７−テトラヒドロ−ピラゾロ［１，５−ａ］ピリミジン誘導体および２，３−ジヒドロ−１Ｈ−イミダゾ［１，２−ｂ］ピラゾール誘導体
EP3134406A1 (en) * 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors
US10584118B2 (en) 2015-06-22 2020-03-10 Actelion Pharmaceuticals Ltd NADPH oxidase 4 inhibitors
JP6508721B2 (ja) 2015-09-28 2019-05-08 株式会社Ｓｃｒｅｅｎホールディングス 基板処理方法および基板処理装置
WO2019141957A1 (en) * 2018-01-19 2019-07-25 Cado Biotechnology Ivs N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof

Also Published As

Publication number Publication date
EP4105206A1 (en) 2022-12-21
JP2023511302A (ja) 2023-03-17
AU2021208915B2 (en) 2024-02-22
US20230067461A1 (en) 2023-03-02
IL294674A (en) 2022-09-01
WO2021145655A1 (ko) 2021-07-22
KR102333863B1 (ko) 2021-12-03
AU2021208915A1 (en) 2022-09-01
MX2022008665A (es) 2022-08-10
KR20210091063A (ko) 2021-07-21
CN114945561A (zh) 2022-08-26
CA3167675A1 (en) 2021-07-22
BR112022013849A2 (pt) 2022-09-13
CO2022010431A2 (es) 2022-08-09

Similar Documents

Publication Publication Date Title
NI202000092A (es) Compuestos
CO2022010431A2 (es) Nuevo derivado de pirazol
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
UY36712A (es) Derivados de pirimidiniloxi benceno como herbicidas
ECSP20035590A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
CO2021001849A2 (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende
ECSP21015020A (es) Pirazoles fungicidas sustituidos con nitroanilino
DOP2020000077A (es) Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene
CL2023000200A1 (es) Nuevo derivado de pirazol
CO2018007668A2 (es) Composición para el control de plagas y método para el control de plagas
CO2021017706A2 (es) Pirrolidinonas sustituidas con pirazol como herbicidas
MX2018004055A (es) Compuestos de imino con un sustituyente de 2-cloropirimidin-5-ilo como agentes de control de plagas.
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
CL2019002025A1 (es) Derivados de pirrolotriazina como inhibidor de cinasas.
AR083438A1 (es) Composicion que controla las plagas y metodo para controlarlas
CR10979A (es) Combinacion de herbicidas
CO2019005949A2 (es) Combinación herbicida que contiene triafamona e indaziflam
CL2022001511A1 (es) Procesos e intermediario para la preparación de oxetan-2-ilmetanamina
AR115689A1 (es) Compuestos de uracilo y su utilización
AR125853A2 (es) Composición farmacéutica de una sal hemisulfato de un compuesto nucleotídico
GT200600132A (es) Una oxindoloxazolidinona como agente antibacteriano
MY189798A (en) Novel biphenyl compound or salt thereof